Recent evidence from nine adult cancer cell lines has shown that BRD4 inhibitors can be used to convert MMR-proficient (pMMR) tumors into MMR-deficient (dMMR) tumors by decreasing the expression level of key MMR genes. This evidence concerns the gene MRC1 and cancer.